ArticleChinese medicine2025
Aster tataricus extract and its active compounds display a broad spectrum of antiviral activity in vitro and in vivo.
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAster tataricus, a perennial terrestrial herb with a rich history of use in traditional medicine, is renowned for its therapeutic properties. However, despite the widespread use of Aster tataricus, its antiviral efficacy and mode of action against viruses have not yet been studied. Here, we demonstrated that Aster tataricus extract (ATE) has antiviral effects and an underlying mechanism of action both in vitro and in vivo.
methodsAntiviral effect of ATE was assessed against Influenza A virus (PR8), Newcastle Disease Virus (NDV), and Herpes Simplex Virus-1 (HSV) in RAW264.7 cells. Mechanism was explored by analyzing the induction of antiviral immune responses, including type-I interferon (IFN) signaling and cytokine secretion. In vivo, BALB/c mice were treated with ATE prior to infection with lethal influenza A subtypes, A/PR/8/34 (H1N1), A/Aquatic bird/Korea/W81/2005 (H5N2), and A/Chicken/Korea/116/2004 (H9N2). Survival rates, viral titers, and lung pathology were measured. High-performance liquid chromatography (HPLC) was used to identify active compounds in ATE, and their antiviral effects were further investigated.
resultsAn effective dose of ATE significantly inhibited influenza A virus (PR8), NDV, and HSV replication in RAW264.7 cells. Mechanistically, we found that ATE induced an antiviral state, which includes upregulation of type-I interferon signaling and secretion of IFNs and pro-inflammatory cytokines in RAW264.7 cells. In vivo, ATE treatment showed increased survival due to reduced viral titers and less severe pathological changes in the lung, and the observed prophylactic effects were associated with increased secretion of IL-6, IFN-γ, and IFN-β in bronchoalveolar lavage fluid. Based on the reported information and HPLC analysis, quercetin, kaempferol, and ferulic acid were identified as active compounds in the aqueous fraction, and an effective dose of each compound exhibited antiviral effects similar to ATE against influenza viruses.
conclusionsThese findings suggest that ATE and its active compounds act as immunomodulators and may be potential candidates as a source of promising natural antivirals for animals and humans.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.